Skip to content
Complete your sign in
→
Close
Complete your sign in
→
Close
Complete your sign up
→
Close
Complete your sign in
→
Close
Complete your sign in
→
Close
Confirm your newsletter sign up
→
Close
Confirm your newsletter sign up
→
Close
Confirm your newsletter sign up
→
Close
Complete your sign in
→
Close
Open main menu
Search
Get
the
app
Subscribe
Sign in
Open account menu
Close panel
Subscribe
Sign in
Search
Home
Finance
Politics
Technology
Law
Media
Ideas
Newsletters
On The Call
Group subscriptions
Close panel
Subscribe
Newsletters
Your account
Sign out
Home
Finance
Politics
Technology
Law
Media
Ideas
On The Call
Newsletters
Neuren Pharmaceuticals
ASX:NEU
Page 2
Briefing
New Path
Neuren Pharmaceuticals recieves FDA designation
19 July 2024
Briefing
Positive Results
Neuren shares rise on encouraging drug trial
27 May 2024
Briefing
Sales Miss
Neuren shares dive as US Daybue sales fall short of guidance
9 May 2024
Briefing
Growth Plans
Neuren outlines higher royalties from US drug
24 April 2024
Briefing
Drug Test
Neuren shares rise on treatment accepted for Canada review
23 April 2024
Briefing
Drug Test
Neuren Pharmaceuticals shares lift 4.7% on profit results
1 March 2024
Briefing
Drug Test
Neuren shares plunge 14% on US Daybue sales
28 February 2024
Briefing
Short Fall
Neuren hits back at Culper claims, shares plunge over 13%
16 February 2024
Close
Email
Processing
Sign up
Let me know about Capital Brief updates and subscription offers.
Your email address will be stored in accordance with our
privacy policy
.
Close
